Longevity science in London has moved from the fringe to the boardroom. The £50,000 annual protocol — once the province of Silicon Valley biohackers — is now being adopted by UK executives who have concluded that biological age reduction is not a lifestyle choice but a competitive advantage. The question is no longer whether to invest in longevity but how to invest wisely in a market saturated with unsubstantiated claims.
What the Protocol Contains
The £50K annual investment breaks down into four categories: diagnostics (£15K), therapeutics (£18K), monitoring (£9K), and lifestyle infrastructure (£8K). The diagnostics layer — epigenetic clock testing, full-body MRI, continuous glucose monitoring, and advanced cardiac screening — provides the baseline data that makes everything else possible. The therapeutics layer is where the science is most contested and the claims most exaggerated. Our analysis separates the evidence-based interventions from the aspirational ones.
The monitoring layer — wearable analytics, sleep architecture tracking, and quarterly blood panel reviews — closes the feedback loop. The lifestyle infrastructure — environmental optimisation, recovery protocols, and circadian alignment — provides the sustained conditions that allow the other three layers to compound.